RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a novel therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™), to deliver chemotherapy to difficult-to-treat tumors. This innovative therapy utilizes RenovoRx’s lead product candidate, RenovoGem™(intra-arterial gemcitabine in combination with the proprietary RenovoCath® delivery system) and is currently under investigation to increase survival and improve quality of life for pancreatic cancer patients. This platform technology will enable physicians to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy. RenovoRx has initially secured FDA Orphan Drug Designation for RenovoGem for two indications including pancreatic cancer and cholangiocarcinoma (bile duct cancer, or CCA).
RenovoRx’s patent portfolio currently includes seven issued US patents and one European patent for its technology with several additional patents pending in the US, Europe, and Asia.